Takeda submits IBD drug candidate for FDA approval

06/25/2013 | PharmaTimes (U.K.)

Takeda Pharmaceutical has filed a biologics license application with the FDA for approval to use its experimental monoclonal antibody drug vedolizumab as a treatment for moderately to severely active Crohn's disease and ulcerative colitis. The application was based on data from four late-stage international trials involving 2,700 patients.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI